Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
about
Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of lifePsychotic disorders in children and adolescents: a primer on contemporary evaluation and managementAssessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study resultsLong-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with SchizophreniaClinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America.Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychoticsRole of long-acting injectable second-generation antipsychotics in the treatment of first-episode schizophrenia: a clinical perspective.Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia.Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons.Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia.Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?The relationship between patient satisfaction and treatment outcomes in schizophrenia.Use of depot antipsychotic medications for medication nonadherence in schizophreniaPaliperidone: a new extended-release oral atypical antipsychotic.Risperidone long-acting injection: a review of its long term safety and efficacy.Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trialA New Psychosocial Tool for Gaining Patient Understanding and Acceptance of Long-acting Injectable Antipsychotic Therapy.Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review.Long-acting injectable antipsychotics in early psychosis: a literature review.Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement.Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia.Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission iNew for old? Risperidone long-acting injection in older patients.Effectiveness and tolerability of long-acting risperidone: A 9-month open-label extension of a 12-week switching study from oral antipsychotics.
P2860
Q26752965-AF88ACD5-5819-4CFF-9D62-490BCE523B98Q33975802-4285EFA7-4935-4F0C-A9BB-E1A10B27AD62Q34048194-CDCC884E-7429-4634-A01F-4608DE9C9980Q34386881-846B6F40-40FB-47FC-8446-EB1656B65AF9Q34444162-9687B258-7CAF-4DB4-BC73-F359D27169F5Q34560335-A958239B-1141-49AA-9406-A763674AD3F5Q36121675-922A5891-CC30-4980-B077-A4A1F6CFC853Q36168916-3EC42AF3-B6F6-4A92-946D-D9F425C93ABBQ36169091-78D8D4B6-37A0-4069-A86D-F6D2771993F0Q36183650-B42D2614-C514-45D5-A094-261093B1BCD0Q36202865-3472D3B4-074D-4836-A3B7-A8BC5F56E6DCQ36211694-E7CDCAD9-14B8-4356-A719-11010E62AF87Q36626251-A375D45E-CD5C-43B1-A1E8-5830F9612C82Q36842947-B7925363-C458-484E-A2DD-915096D6C35BQ36967269-4F368156-667B-41AC-8D0A-3CAC8D9BDE9AQ37062563-2F22826D-518B-4E1E-9E69-3D729A905B1CQ37078993-F098AC7D-8415-414D-8C7B-6998F6D24E58Q37272606-0D895728-0138-4D11-B260-F52416607545Q37356486-98A9A1A9-D140-4DE7-8BAD-E4003C286E39Q37418931-3CA31559-3242-47B0-8A0C-362FE2763096Q37778398-17CE021F-8B4C-4B87-8933-E532181258E2Q38064842-5D94A235-6570-4001-B26C-17F423F58016Q38076170-EF8A9B67-DA6E-4A37-9712-259C7D3CCC50Q38403164-248F2A03-AA3E-4EE8-AA2D-E73F82FF542FQ38592404-99C240FF-931E-4E50-AE5D-B6BCBFDE88C0Q38851847-6E604435-250A-4941-8EE7-8A8CB6CF349FQ42659773-FDD53CD7-587F-4245-A593-DCD0A4B477ECQ44830864-F7B58DF4-0C65-4E47-8331-28ED26FBEC10Q46902589-036DF533-211D-47ED-A6CC-F398B3B3E282Q48414001-A626DEA1-0EED-427D-B0BF-93E9608423EA
P2860
Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Patients in the early phases o ...... ridone long-acting injectable.
@en
Patients in the early phases o ...... ridone long-acting injectable.
@nl
type
label
Patients in the early phases o ...... ridone long-acting injectable.
@en
Patients in the early phases o ...... ridone long-acting injectable.
@nl
prefLabel
Patients in the early phases o ...... ridone long-acting injectable.
@en
Patients in the early phases o ...... ridone long-acting injectable.
@nl
P2093
P2860
P356
P1476
Patients in the early phases o ...... ridone long-acting injectable.
@en
P2093
M St John Turner
R Andrezina
V Milanova
P2860
P356
10.1177/0269881105056513
P407
P433
P577
2005-09-01T00:00:00Z